Structure Therapeutics Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Structure Therapeutics Inc. (GPCR) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$1.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-06
- Structure Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$1.25M.
- Structure Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$3.25M.
- Structure Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $229.00K.
- Structure Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $463.00K, a 86.08% decline year-over-year.
- Structure Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $140.00K, a 64.38% decline from fiscal 2024.
- Structure Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $393.00K, a 37.72% decline from fiscal 2023.
- Structure Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $631.00K.
- Structure Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$110.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.25M 10-Q · filed 2026-08-06 | -$4.50M 10-Q · filed 2026-08-06 | -$4.27M derived: sum of 3 quarters · filed 2026-08-06 | -$3.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$3.25M 10-Q · filed 2026-05-07 | -$3.02M derived: sum of 2 quarters · filed 2026-05-07 | -$2.56M derived: sum of 3 quarters · filed 2026-05-07 | -$3.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $229.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $692.00K derived: sum of 2 quarters · filed 2026-02-26 | $239.00K derived: sum of 3 quarters · filed 2026-08-06 | $140.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $463.00K 10-Q · filed 2025-11-06 | $10.00K derived: sum of 2 quarters · filed 2026-08-06 | -$89.00K 10-Q · filed 2025-11-06 | -$2.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$453.00K 10-Q · filed 2026-08-06 | -$552.00K 10-Q · filed 2026-08-06 | -$2.48M derived: sum of 3 quarters · filed 2026-08-06 | $849.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$99.00K 10-Q · filed 2026-05-07 | -$2.02M derived: sum of 2 quarters · filed 2026-05-07 | $1.30M derived: sum of 3 quarters · filed 2026-05-07 | $905.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.40M derived: sum of 2 quarters · filed 2026-02-26 | $1.00M derived: sum of 3 quarters · filed 2026-02-26 | $393.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.33M 10-Q · filed 2025-11-06 | $2.93M derived: sum of 2 quarters · filed 2025-11-06 | $2.32M 10-Q · filed 2025-11-06 | $3.15M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$397.00K 10-Q · filed 2025-08-06 | -$1.01M 10-Q · filed 2025-08-06 | -$177.00K derived: sum of 3 quarters · filed 2026-02-26 | -$97.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$611.00K 10-Q · filed 2025-05-08 | $220.00K derived: sum of 2 quarters · filed 2026-02-26 | $300.00K derived: sum of 3 quarters · filed 2026-02-26 | -$237.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $831.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $911.00K derived: sum of 2 quarters · filed 2026-02-26 | $374.00K derived: sum of 3 quarters · filed 2026-02-26 | $631.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $80.00K 10-Q · filed 2024-11-13 | -$457.00K derived: sum of 2 quarters · filed 2024-11-13 | -$200.00K 10-Q · filed 2024-11-13 | -$175.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$537.00K 10-Q · filed 2024-08-08 | -$280.00K 10-Q · filed 2024-08-08 | -$255.00K derived: sum of 3 quarters · filed 2024-08-08 | -$305.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $257.00K 10-Q · filed 2024-05-09 | $282.00K derived: sum of 2 quarters · filed 2024-05-09 | $232.00K derived: sum of 3 quarters · filed 2024-05-09 | $182.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$25.00K derived: sum of 2 quarters · filed 2024-03-08 | -$75.00K derived: sum of 3 quarters · filed 2024-03-08 | -$110.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | -$50.00K 10-Q · filed 2023-11-17 | -$100.00K derived: sum of 2 quarters · filed 2023-11-17 | -$135.00K 10-Q · filed 2023-11-17 | |
| 2022-06-30 | -$50.00K 10-Q/A · filed 2023-11-17 | -$85.00K 10-Q/A · filed 2023-11-17 | ||
| 2022-03-31 | -$35.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |